rs4149268 — ABCA1
Intronic ABCA1 variant — the C allele tags a liver enhancer that boosts ABCA1 expression, raising HDL-cholesterol; T-allele homozygotes show modestly lower HDL and elevated cognitive decline risk
Details
- Gene
- ABCA1
- Chromosome
- 9
- Risk allele
- T
- Clinical
- Risk Factor
- Evidence
- Moderate
Population Frequency
Category
Cholesterol & LipoproteinsSee your personal result for ABCA1
Upload your DNA data to find out which genotype you carry and what it means for you.
Upload your DNA dataWorks with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.
ABCA1 — The Cholesterol Efflux Gatekeeper
ABCA111 ATP-Binding Cassette Transporter A1 — a cell-membrane protein that
pumps cholesterol and phospholipids out of cells onto lipid-poor apolipoprotein A-I,
creating nascent HDL particles is the rate-limiting step in reverse cholesterol
transport22 reverse cholesterol
transport
the process by which cholesterol is removed from peripheral tissues and
delivered to the liver for excretion. Without ABCA1, cells cannot shed excess
cholesterol and HDL formation collapses. Loss-of-function mutations in both copies of
ABCA1 cause Tangier disease33 Tangier disease
a rare autosomal recessive disorder characterized by
near-absent HDL, orange-tinged tonsils, and accelerated atherosclerosis; heterozygous
carriers have roughly half-normal HDL levels. rs4149268 operates at a far milder scale —
it is a common intronic variant that fine-tunes how much ABCA1 the liver makes.
The Mechanism
rs4149268 sits in intron 2 of ABCA1 on chromosome 9 (GRCh38 position 104,884,939).
The gene is transcribed from the minus strand, so the C allele reported in genome files
(plus-strand) corresponds to a G in coding-strand notation as used in many papers — these
are the same allele. Functional studies identified a nearby variant, rs2575875, in
near-perfect linkage disequilibrium (r²=0.96) with rs4149268. Richardson et al.44 Richardson et al.
Richardson et al. Allele-specific enhancers mediate associations between LCAT and ABCA1
polymorphisms and HDL metabolism. PLOS One, 2019
showed that the A allele of rs2575875 (tagging the C allele of rs4149268) creates a
STAT355 Signal Transducer and Activator of Transcription 3 — a transcription factor
that activates gene expression in response to cytokines and growth factors binding
site within an intronic enhancer that loops physically to the ABCA1 promoter. Chromatin
immunoprecipitation showed 8-fold enrichment of this allele with anti-STAT3 antibody,
and the enhancer drove allele-specific transcription in liver cell lines. Higher ABCA1
expression means more efficient cholesterol efflux and more nascent HDL particles.
The Evidence
The landmark GWAS meta-analysis by Willer et al.66 landmark GWAS meta-analysis by Willer et al.
Willer et al. Newly identified loci
that influence lipid concentrations and risk of coronary artery disease. Nature Genetics,
2008 in 8,816 individuals (with replication
in 11,569) found that rs4149268-C carriers had approximately +0.82 mg/dL higher
HDL-cholesterol compared to T/T homozygotes (p=10⁻¹⁰). The effect is small in absolute
terms — HDL levels typically range from 40 to 80 mg/dL — but the association was
genome-wide significant and biologically coherent with the ABCA1 pathway.
Replication in diverse populations has been mixed: the PAGE study77 PAGE study
Dumitrescu et al.
Genetic determinants of lipid traits in diverse populations from the PAGE study. PLOS
Genetics, 2011 could not replicate the
association in European Americans despite 99% statistical power, suggesting the effect
may be smaller than the original estimate implied or population-specific. The T allele
reaches ~67% frequency in African populations (versus ~38% in Europeans), which affects
absolute HDL distribution in those ancestries.
A study in a Chinese cohort (n=1,654) found that TT homozygotes were 1.76 times more
likely to have mild cognitive impairment88 mild cognitive impairment
MCI — a clinically recognized transitional
state between normal aging cognition and dementia, with impairment in memory or other
domains that does not yet meet dementia criteria than CC homozygotes (OR 1.76,
95% CI 1.11–2.80). This likely reflects the known link between chronically low HDL and
neurodegeneration, as ABCA1 drives cholesterol efflux in neurons and astrocytes, not
just hepatocytes.
Practical Actions
The effect size of rs4149268 on HDL is modest — roughly 0.82 mg/dL per C allele. For TT homozygotes, the genotype itself is not a clinical diagnosis of low HDL; many TT individuals have perfectly normal HDL levels due to lifestyle and other genetic factors. The priority is knowing your measured HDL, then targeting the lifestyle drivers that have the largest HDL-raising effect in people with genetically modest ABCA1 activity: regular aerobic exercise (the strongest HDL lifter), reduction of trans fats, and niacin-equivalent dietary choices. If HDL is confirmed low, discussion with a clinician about whether pharmacological support is appropriate is warranted.
Interactions
ABCA1 does not act alone. APOE ε499 APOE ε4
rs429358 C allele — the APOE4 determinant that
impairs LDL clearance and amyloid removal and ABCA1 T-allele homozygosity converge
on the same pathway: both reduce brain cholesterol homeostasis and are independent risk
factors for cognitive decline. Carrying ABCA1 TT alongside APOE4 may produce additive
vulnerability to neurodegeneration, though direct compound studies at these two loci
specifically are limited. The R219K variant in ABCA1 (rs2230806), studied extensively
for HDL effects, acts through a different mechanism (missense, not enhancer regulation)
and can interact with rs4149268 within the same gene.
Nutrient Interactions
Genotype Interpretations
What each possible genotype means for this variant:
Favorable ABCA1 activity — genetically higher HDL tendency
The C allele at rs4149268 is in near-perfect LD (r²=0.96) with the A allele of rs2575875, an intronic enhancer variant that creates a functional STAT3 binding site. STAT3 binding drives allele-specific transcription of ABCA1 in liver cells, increasing the transporter's expression and improving the rate of cellular cholesterol loading onto apolipoprotein A-I to form nascent HDL particles.
In the Willer et al. GWAS meta-analysis (n > 20,000), each C allele was associated with approximately +0.82 mg/dL higher HDL-C at genome-wide significance (p=10⁻¹⁰). In African populations, the T allele is much more common (~67%), making CC homozygosity more distinctly favorable in that context.
One copy of the HDL-favoring C allele — average cholesterol efflux
Because rs4149268 shows additive dosage effects on HDL-C, CT heterozygotes fall between CC and TT genotypes. Each T allele substitution reduces the number of high-efficiency ABCA1 enhancer copies, modestly reducing hepatic cholesterol efflux capacity. For most CT carriers, this is a background factor rather than a clinically actionable finding — diet, aerobic exercise, and weight have far larger HDL effects than this single intronic variant.
Two copies of the lower-HDL T allele — reduced ABCA1 enhancer activity
TT homozygotes are missing both copies of the rs2575875-linked STAT3 enhancer. Without this enhancer allele, ABCA1 transcription in liver cells is less efficient, reducing the rate at which cells export cholesterol onto apolipoprotein A-I to form HDL particles. Over decades, chronically lower HDL correlates with greater cardiovascular event risk and impaired reverse cholesterol transport.
The cognitive impairment finding (OR 1.76, 95% CI 1.11–2.80 in a Chinese cohort) is biologically plausible: ABCA1 is highly expressed in the brain, where it drives cholesterol efflux from neurons and astrocytes. Chronically reduced ABCA1 activity can impair neuronal membrane cholesterol homeostasis and, in combination with APOE genotype, increase amyloid burden.
The original GWAS effect size of ~0.82 mg/dL per allele is modest. If your measured HDL is normal, the genotype is a background risk factor rather than an indication for treatment. If HDL is confirmed low, targeted interventions can substantially raise it.